[
    {
        "utterance": "Jae Sung: Hi everybody. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Emily Balskus: Hi Emily. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Hi. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Emily, it's nice to see you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Emily Balskus: Yeah, nice to see you too. Looks like we're going to do this uh facilitate this one together. ",
        "annotations": {
            "Supportive response": "Emily expresses agreement and positivity towards the collaborative approach.",
            "Acknowledge contribution": "Emily acknowledges the collaborative situation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, sounds great. ",
        "annotations": {
            "supportive response": "Rosa Krajmalnik-Brown expresses agreement and a positive sentiment towards the facilitation arrangement."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So should we start by going around the room introducing everyone, everyone introducing themselves? ",
        "annotations": {
            "propose new idea": "The speaker introduces a new suggestion for how the group should start their meeting.",
            "process management": "The speaker is managing the meeting flow by suggesting an activity for the group to start with."
        }
    },
    {
        "utterance": "Emily Balskus: Yeah, that sounds good. ",
        "annotations": {
            "supportive response": "Expressing agreement with Rosa's suggestion to introduce everyone."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: You want to start, Emily? ",
        "annotations": {
            "encourage participation": "The utterance invites Emily to start the introductions, encouraging her participation.",
            "process management": "The utterance manages the meeting flow by determining who will start the introductions."
        }
    },
    {
        "utterance": "Emily Balskus: Yeah, yeah, that'd be great. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement and positivity towards proceeding with the suggested action, which aligns with the definition of a supportive response."
        }
    },
    {
        "utterance": "Emily Balskus: Um so I'm Emily Balskus, I'm in the chemistry department at Harvard University. My lab studies gut bacterial metabolism and enzymes and also develops chemical tools to manipulate and study metabolic activities in microbiomes. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to the task by mentioning her department, university, and lab's study areas."
        }
    },
    {
        "utterance": "Emily Balskus: And yeah, do you want to just sort of have uh each person then, you know, introduce the next person. Okay. ",
        "annotations": {
            "ask question": "The speaker is seeking agreement or confirmation on the proposed method of introduction.",
            "process management": "The speaker is managing the meeting flow by suggesting a way to proceed with introductions."
        }
    },
    {
        "utterance": "Emily Balskus: Yeah, so maybe um uh Will, you could go next. ",
        "annotations": {
            "encourage participation": "The speaker invites Will to introduce himself, encouraging his participation in the meeting.",
            "process management": "The speaker is facilitating the meeting by inviting the next person to introduce themselves, which relates to managing the meeting's flow."
        }
    },
    {
        "utterance": "Will Ludington: Hello, um I'm Will Ludington, I'm at the Carnegie Institution uh and the John Hopkins Biology Department. Um I my lab studies uh gut bacteria in fruit flies and uh think about uh kind of complex uh interactions um in microbial communities. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his own expertise and qualifications related to the task by sharing his affiliations and describing his lab's research focus."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So you lead us to the next person. You tell us who the next person is. ",
        "annotations": {
            "process management": "This code applies because Rosa Krajmalnik-Brown is managing the flow of the meeting by passing on the responsibility to introduce the next person.",
            "assign task": "This code applies because Rosa Krajmalnik-Brown is directly assigning a task to someone (implied, not directly addressed) to introduce the next person."
        }
    },
    {
        "utterance": "Will Ludington: Oh, I choose the next one. Sorry. Um uh Elizabeth. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by deciding whose turn it is next to introduce themselves.",
            "encourage participation": "The speaker is encouraging participation by calling out the next person, Elizabeth, to introduce herself."
        }
    },
    {
        "utterance": "Will Ludington: Bess is uh next uh on my screen. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it is primarily a transitional statement."
        }
    },
    {
        "utterance": "Elizabeth Bess: Hi folks. Um I'm Elizabeth, I'm from UC Irvine. I'm in the Department of Chemistry. My uh lab studies the chemical reactions happening in the the gut um by facilitated by bacteria. We're really interested um specifically right now we're really interested in and I'm excited about discussion about metal ions, ionciation, um and also um metabolites that are produced by bacteria and consumed uh by bacteria. ",
        "annotations": {
            "signal expertise": "Elizabeth explicitly states her own expertise and qualifications related to the task by mentioning her lab's research focus and her department."
        }
    },
    {
        "utterance": "Elizabeth Bess: Speak to the next person. ",
        "annotations": {
            "encourage participation": "She is encouraging someone else to participate by taking the turn to introduce the next person.",
            "process management": "She is managing the meeting process by directing how the introductions should proceed."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Oh, I'm sorry. Yes. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Elizabeth Bess: Um uh Linea. ",
        "annotations": {
            "encourage participation": "The speaker invites Linea to introduce themselves, encouraging participation.",
            "process management": "The utterance helps manage the meeting flow by moving to the next person's introduction."
        }
    },
    {
        "utterance": "Linnea Freeman: Hi everyone, I'm Linnea Freeman. I'm at Furman University in the Biology Department and the Neuroscience program. Um my lab looks at sex differences in response to consumption of a high fat, high sugar diet. Um we look at the microbiome changes, but um my my area is more in the brain and we look at neuroinflammation. Uh we focus on astrocytes and microglia. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own background and area of expertise."
        }
    },
    {
        "utterance": "Linnea Freeman: Um Lisa. ",
        "annotations": {
            "encourage participation": "Linnea Freeman is attempting to involve Lisa in the conversation by mentioning her name, likely to encourage her participation or introduction."
        }
    },
    {
        "utterance": "Lisa Osborne: Okay, uh I'm at UBC in Vancouver BC Canada. We study uh neuroinflammation in the context of EAE, so a mouse model of MS. We have a germ free facility here and right now most of our studies are focusing on the effect of an aging microbiota, um dietary interventions that can modulate EAE outcomes and how helmets, so these worms that get into the gut, how they influence EAE outcomes and we're particularly interested um in how things that happen in the gut influence CNS resident uh populations and inflammation. ",
        "annotations": {
            "signal expertise": "Lisa explicitly states her own expertise and her lab's qualifications related to the task."
        }
    },
    {
        "utterance": "Lisa Osborne: So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lisa Osborne: And I will go to Jay, I think is the next one. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by indicating she will introduce the next person, Jay."
        }
    },
    {
        "utterance": "Jae Sung: Oh. Thanks Lisa. Um hi everybody, I'm Jay Song. I'm up here in uh uh Mayo Clinic in uh Rochester, Minnesota. Um our group is a computational biology and bioinformatics lab. We take a multi-omics approach to study patients with uh with uh autoimmune disease in particular rheumatoid arthritis and vasculitis. ",
        "annotations": {
            "signal expertise": "Jay explicitly states his lab's expertise and qualifications in the field of computational biology and bioinformatics."
        }
    },
    {
        "utterance": "Jae Sung: Um so that's kind of more on the clinical and translational side. On the more basic science side, we do uh uh bioinformatics studies um of uh microbial genomes to identify what chemicals, natural products they could be producing and how those uh chemicals could influence uh uh host disease um in the context of autoimmunity. ",
        "annotations": {
            "signal expertise": "Jae Sung is explicitly stating his group's expertise in computational biology and bioinformatics."
        }
    },
    {
        "utterance": "Jae Sung: Um okay, so next I'm going to um send this hot potato to Rosa. ",
        "annotations": {
            "express humor": "Jae Sung makes a joke by using the phrase 'send this hot potato to Rosa.', which is a humorous way to pass responsibility.",
            "process management": "Jae Sung is managing the meeting flow by passing the responsibility to Rosa."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Thank you for not sending the hot potato earlier because there was vacuuming here in the background. ",
        "annotations": {
            "Express humor": "The speaker makes a light comment about 'hot potato' and vacuuming noise, which can be seen as humorous.",
            "Supportive response": "The speaker expresses appreciation for not being passed the responsibility earlier, showing a positive and supportive tone."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So I appreciate that. ",
        "annotations": {
            "supportive response": "Rosa is expressing a positive sentiment towards Jae Sung's consideration of not sending the hot potato earlier due to background noise."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Uh this is a good time. So I am Rosa Krahnik Brown or Rosie. I'm an environmental engineer by training. Uh but I have been working with the microbiome for the past 13 years, gut microbiome. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to the task, mentioning her background as an environmental engineer and her experience working with the microbiome."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: My my group um uh is interested in um metabolism, how the gut microbiome changes metabolisms and might change um energy extraction by the host, but we also have done a lot of work with autism and the microbiome. And so we look at micro microbe interactions, we look at the environment, of course, and we also look at chemicals, metabolites being produced by these microbes. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her group's expertise in areas related to microbiome research, including metabolism, autism, microbe interactions, and chemical production.",
            "identify gap": "The speaker implies gaps in knowledge that her group can fill, particularly in understanding microbiome interactions and its relation to disease.",
            "develop idea": "The speaker slightly expands on the concept of microbiome research and its applications, particularly in metabolism and autism."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I need to pass it to someone else, of course, and I was forgetting, but I got it. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by determining who should take the next action, in this case, passing the responsibility to someone else or confirming she has it."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Uh I know Emily was going to remind me. ",
        "annotations": {
            "process management": "The utterance is about managing the meeting flow, specifically regarding who was to introduce themselves next.",
            "None": "No other code seems to directly apply as the utterance doesn't introduce a new idea, ask a question, signal expertise, identify a gap, or perform any other action that would categorize it under the provided codes."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Uh Pamela. ",
        "annotations": {
            "encourage participation": "Rosa is inviting Pamela to introduce herself, encouraging her participation.",
            "process management": "Rosa is managing the meeting flow by indicating it's time for the next person to introduce themselves."
        }
    },
    {
        "utterance": "Emily Balskus: Hi everyone. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Pamela Chang: Hi everyone. Uh my name is Pam Chang. I'm an assistant professor at Cornell. Uh I'm in the Department of Microbiology and Immunology. I'm trained as a chemical biologist and immunologist and my lab um studies the interactions between the gut microbiota and the host immune system um via small molecule metabolites. ",
        "annotations": {
            "signal expertise": "Pamela explicitly states her own expertise and qualifications related to her work in microbiology and immunology."
        }
    },
    {
        "utterance": "Pamela Chang: We use mouse models of inflammatory bowel disease and infection. We're interested in the gut brain axis obviously. Um and the other half of my lab works on developing chemical tools to probe the metabolism of the gut microbiota and uh this we're really interested in looking at enzymatic activities carried out by uh bacteria in the gut. ",
        "annotations": {
            "develop idea": "Pamela Chang is expanding on her lab's research, providing details about their work on mouse models of inflammatory bowel disease, the gut-brain axis, and developing chemical tools to study gut microbiota metabolism."
        }
    },
    {
        "utterance": "Pamela Chang: And then now I'll pick Tom. ",
        "annotations": {
            "process management": "This code applies because Pamela Chang is managing the meeting flow by selecting the next person to introduce themselves."
        }
    },
    {
        "utterance": "Tom Mansell: Hey, that's good. ",
        "annotations": {
            "supportive response": "Tom is expressing a positive sentiment towards the discussion or introduction.",
            "acknowledge contribution": "Tom is also acknowledging the introduction or previous discussion."
        }
    },
    {
        "utterance": "Tom Mansell: I actually went to Cornell for my PhD, so. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Um so uh I'm Tom Mansel, I'm from Iowa State University. I'm in chemical engineering. ",
        "annotations": {
            "signal expertise": "Tom explicitly states his own expertise or qualifications related to the task by mentioning his name, university, and department."
        }
    },
    {
        "utterance": "Tom Mansell: And uh our lab focuses on uh our goal is to engineer live biotherapeutics. So uh enabling uh engineered probiotics to secrete small molecules or peptides or proteins that would have a therapeutic effect on the host. ",
        "annotations": {
            "clarify goal": "The speaker is defining their lab's goal and focus area.",
            "signal expertise": "The speaker is implicitly stating their expertise by describing their lab's focus and area of work."
        }
    },
    {
        "utterance": "Tom Mansell: Um and so my goal here is to uh kind of find targets. ",
        "annotations": {
            "clarify goal": "Tom is stating his goal of finding targets, which clarifies his objective."
        }
    },
    {
        "utterance": "Tom Mansell: We focus a lot on the chassis uh right now and so uh my goal is to find small molecule metabolites that would be good to have around or get rid of um and uh so I think this discussion will be good for that. I hope. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on their current work focus and goal.",
            "signal expertise": "The speaker is stating their current work and goal, which implicitly signals their expertise.",
            "clarify goal": "The speaker defines their goal, which is to find small molecule metabolites."
        }
    },
    {
        "utterance": "Tom Mansell: And I'll throw it to Mark. ",
        "annotations": {
            "process management": "Tom Mansell is managing the meeting flow by passing the turn to Mark."
        }
    },
    {
        "utterance": "Mark Mimee: Thanks Tom. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mark Mimee: Um so my name is Mark Mimi. I'm an assistant professor at the University of Chicago in the Department of Microbiology and the School of Molecular Engineering. ",
        "annotations": {
            "signal expertise": "The speaker is explicitly stating his own expertise and qualifications related to the task by mentioning his position as an assistant professor at the University of Chicago in the Department of Microbiology and the School of Molecular Engineering."
        }
    },
    {
        "utterance": "Mark Mimee: And my group is essentially uh a synthetic biology microbiome group. So we're really interested. ",
        "annotations": {
            "signal expertise": "Mark is explicitly stating his group's area of expertise and interest.",
            "None": "No other codes strongly apply as the utterance primarily serves to introduce Mark's group."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: think. ",
        "annotations": {
            "encourage participation": "The speaker is encouraging others to contribute their thoughts or ideas, even if minimally."
        }
    },
    {
        "utterance": "Unidentified Speaker: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Unidentified Speaker: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Will Ludington: Can I start with a question based on reading that question? ",
        "annotations": {
            "ask question": "The speaker is requesting permission to ask a question, which is a direct request for information about the appropriateness of his question."
        }
    },
    {
        "utterance": "Will Ludington: Or a set of questions. ",
        "annotations": {
            "ask question": "The speaker explicitly states a desire to ask a question or a set of questions, directly requesting information or clarification."
        }
    },
    {
        "utterance": "Will Ludington: Um, so when I think about like neurons and brain, I think of like when information is transmitted it's through a synapse is like really uh tightly coupled way to control how the information is transmitted. Um, when I think about like microbial community, I don't I mean like I don't know where that synapse is to even get the bacteria signal there was a secretone part in here. Like how does the bacterial signal get sensed in the first place and are the are the like the abundance of these metabolites enough to like stimulate a signal and are there enough channels, specific channels that could sense one of these metabolites that the bacteria would be uh producing or is it more of an aggregate signal uh from the whole community that's being sensed or uh so be able to point out that it might be like specific molecules that are really important. ",
        "annotations": {
            "ask question": "The speaker is requesting information, clarification, or expertise on a prior statement or idea proposed by another group member.",
            "develop idea": "The speaker is expanding, building upon, or elaborating existing ideas through reasoning, examples, clarification, and evidence."
        }
    },
    {
        "utterance": "Will Ludington: Um that is the kind of the point of some of the questions in there. And I'm just curious like to hear people's thoughts about you know, is it one thing that's being sensed or is it kind of a profile things being sensed and how is, you know, if it is one thing like how is is there a directed channel for that thing or is it kind of a distributed network? Um is there a synapse or is there a distributed network that's kind of pulling that signal in? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on how bacterial signals, particularly in the form of metabolites, are sensed by the host, making this an explicit question."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Does anyone know? ",
        "annotations": {
            "ask question": "Rosa is requesting information or insight from others regarding Will Ludington's previous question.",
            "encourage participation": "Rosa is inviting others to contribute their thoughts or expertise."
        }
    },
    {
        "utterance": "Pamela Chang: I'll speak to this. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it is a simple offer to contribute to the discussion."
        }
    },
    {
        "utterance": "Pamela Chang: Um, so I think that the field is is taking more of a reductionist approach because it's easier to rack your head around, you know, what one metabolite might do or what one family of metabolites might do. But I think that we really should be thinking systemically. I think you're getting at the question of there's as somebody alluded to earlier, thousands of metabolites and they all if they all have activities, what is the summation of all their activities. ",
        "annotations": {
            "develop idea": "Pamela Chang is expanding on the idea of studying metabolites by suggesting a shift from a reductionist to a systemic approach.",
            "ask question": "Pamela Chang poses a rhetorical question about the summation of activities of all metabolites, guiding the discussion."
        }
    },
    {
        "utterance": "Pamela Chang: And so I think that's probably more likely that what's going on in vivo, um, although, you know, I think that we're as a field just coming toward that, um, that question. Uh and I think it's a really interesting one for sure. ",
        "annotations": {
            "Develop Idea": "Pamela is expanding on the existing discussion about the complexity of metabolite signals and how they are sensed, suggesting a systemic view of the problem.",
            "Supportive Response": "Pamela is also showing support for the line of questioning by finding the topic interesting and contributing to the discussion."
        }
    },
    {
        "utterance": "Pamela Chang: But yeah, bottom line, I don't think we know. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes a lack of knowledge in a particular domain, in this case, how bacterial signals are sensed and interpreted."
        }
    },
    {
        "utterance": "Jae Seungh: Probably all of all of the above will. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with previous comments, indicating a positive evaluation of the ideas discussed."
        }
    },
    {
        "utterance": "Jae Seungh: I mean, like there's receptors in the epithelial lining that respond to um particular antagonist or agonist. ",
        "annotations": {
            "develop idea": "Jae Seungh's statement elaborates on the mechanism of how bacterial metabolites might interact with the host by mentioning specific receptors in the epithelial lining."
        }
    },
    {
        "utterance": "Jae Seungh: Um, microbial produced metabolites could, you know, if you have a leaky gut, they could kind of, you know, the metabolites can find themselves into the circulatory system. ",
        "annotations": {
            "develop idea": "This utterance develops the idea that microbial metabolites could influence the host by explaining a potential mechanism.",
            "propose new idea": "Jae Seungh introduces a specific mechanism of how microbial-produced metabolites could affect the host.",
            "offer feedback": "Jae Seungh provides a specific idea about the interaction between microbial metabolites and the host's circulatory system."
        }
    },
    {
        "utterance": "Jae Seungh: And who knows what happens after that. Um, you can stimulate the um, kind of the inter endocrine cells to actually make and in turn they make, you know, ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea about how microbial metabolites could influence the host, specifically through the stimulation of inter endocrine cells.",
            "ask question": "The speaker poses a question about the consequences of microbial metabolite stimulation, 'And who knows what happens after that'."
        }
    },
    {
        "utterance": "Jae Seungh: different types of hormones um that affect other the activities of different tissues. Um, in regards to synapses at the inter nervous system, definitely um could be one mechanism, but apart from that, there's probably various other ways that microbial products could affect the brain. So complex. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the idea of how microbial products could affect the brain, discussing potential mechanisms."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, along those lines, I don't know if anyone knows about more, but ",
        "annotations": {
            "supportive response": "Mark is expressing agreement or alignment with previous comments.",
            "encourage participation": "Mark is inviting others to share their knowledge."
        }
    },
    {
        "utterance": "Mark Mimee: I know there have been stories that describe like um rather serotonin or serotonin producing sorry, serotonin producing microbes or GABA producing or consuming microbes uh like evoking this notion that making or depleting neurotransmitters affects uh the gut brain axis. ",
        "annotations": {
            "develop idea": "The utterance expands on existing ideas by providing specific examples of microbes and their potential effects on the gut-brain axis.",
            "supportive response": "The utterance validates the concept that microbial products can affect the gut-brain axis, contributing to the discussion in a positive manner."
        }
    },
    {
        "utterance": "Mark Mimee: Has that been shown in different diseases? Like those that microbial activity in the gut to actually affect uh behavior or whatever, you know, neurological phenotype you're looking at. ",
        "annotations": {
            "ask question": "The speaker is requesting information about whether microbial activity in the gut has been shown to affect behavior or neurological phenotypes in different diseases."
        }
    },
    {
        "utterance": "Lisa Osborne: So if I understand your question, you're asking whether or not ",
        "annotations": {
            "ask question": "Lisa Osborne is requesting clarification on Will Ludington's previous question to ensure she understands it correctly."
        }
    },
    {
        "utterance": "Lisa Osborne: there's been a demonstration of microbial communities impacting biological outcome such as uh behavior. ",
        "annotations": {
            "acknowledge contribution": "Lisa Osborne is verbally recognizing a previous point about demonstrations of microbial communities impacting biological outcomes.",
            "supportive response": "Lisa Osborne is expressing agreement or validation for the line of inquiry regarding microbial communities and biological outcomes."
        }
    },
    {
        "utterance": "Mark Mimee: Well, more specifically, um by modulating neurotransmitters. Like I I definitely know that there are papers that have shown that like bug makes this neurotransmitter or it can consume this neurotransmitter. ",
        "annotations": {
            "develop idea": "The speaker is expanding on an existing idea by providing more specific examples or evidence about how microbes can produce or consume neurotransmitters."
        }
    },
    {
        "utterance": "Mark Mimee: And then there's been suggestions that that metabolic activity within the gut has led to, you know, ",
        "annotations": {
            "develop idea": "Mark Mimee is expanding on previous discussions by mentioning suggestions that metabolic activity within the gut has led to certain outcomes, building upon existing ideas."
        }
    },
    {
        "utterance": "Mark Mimee: or will impact the nervous system in some way. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea that microbial activity in the gut could impact the nervous system, building on previous discussions."
        }
    },
    {
        "utterance": "Mark Mimee: Uh but I'm not aware, I'm also not in this field at all, so these studies might be like in the biggest impact journals possible and I'm just completely unaware. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes his lack of knowledge or expertise in a particular area, stating 'I'm also not in this field at all' and 'I'm just completely unaware.'"
        }
    },
    {
        "utterance": "Mark Mimee: Uh I just don't know if uh if that exists. ",
        "annotations": {
            "identify gap": "Mark Mimee explicitly states his lack of knowledge about the existence of certain studies, indicating a gap in his understanding."
        }
    },
    {
        "utterance": "Will Ludington: Yeah, I always hear the serotonin one and it's like when I've like tried to track that down. ",
        "annotations": {
            "ask question": "The speaker is seeking more information about the serotonin connection to microbial activity, indicating a request for clarification or further details."
        }
    },
    {
        "utterance": "Will Ludington: I never find a a really nice I I never find a really nice solid piece of evidence that supports that. ",
        "annotations": {
            "critical response": "Will Ludington is expressing skepticism about the quality of evidence supporting a claim, specifically stating he cannot find solid evidence."
        }
    },
    {
        "utterance": "Will Ludington: I think that they're like these like metabolomic studies show, hey, it's being produced there. Um, but I haven't found the like, you know, it's like it's also said it's in the um, the smooth muscle uh uh these contractions that a lot of that's just uh very local. ",
        "annotations": {
            "identify gap": "Will expresses a lack of clear evidence or understanding regarding the mechanisms of microbial metabolites' effects on the host.",
            "critical response": "Will questions or expresses skepticism about the clarity or existence of evidence for certain claims regarding microbial metabolites' effects."
        }
    },
    {
        "utterance": "Will Ludington: Um but the idea that like, yeah, ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Will Ludington: there's a lot of serotonin there, but is it like ",
        "annotations": {
            "ask question": "Will Ludington is seeking clarification or more information about the role of serotonin, indicating he is asking a question."
        }
    },
    {
        "utterance": "Will Ludington: being used as a neurotransmitter in that case, it might just be a metabolite. ",
        "annotations": {
            "ask question": "The speaker is seeking clarification on the role of serotonin or similar substances produced by microbes, questioning if it's used as a neurotransmitter or just a metabolite.",
            "develop idea": "The speaker is building upon previous discussions about microbial metabolites, exploring their potential functions in the host."
        }
    },
    {
        "utterance": "Will Ludington: So I I totally agree and the serotonin is the one I always ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement with a previous statement, showing a positive evaluation of the discussion on serotonin.",
            "acknowledge contribution": "The speaker is also implicitly acknowledging the contribution of others to the discussion on serotonin by referencing it."
        }
    },
    {
        "utterance": "Will Ludington: like try to track it down, but again, that's not my field, so I would really be curious to know if there is solid evidence for that. ",
        "annotations": {
            "ask question": "Will Ludington is seeking information about the existence of solid evidence for a specific claim.",
            "identify gap": "Will Ludington acknowledges his lack of expertise in the field by stating 'that's not my field'."
        }
    },
    {
        "utterance": "Mark Mimee: in a better way. I was wondering like, should we be thinking of common or molecules that are common with the nervous system or should we be looking for completely novel molecules that are, you know, bacterially derived that um are influencing the nervous system in some way that we don't currently know. ",
        "annotations": {
            "ask question": "Mark Mimee is requesting information or clarification on the approach to studying how bacterially derived molecules influence the nervous system.",
            "develop idea": "Mark Mimee is expanding on the idea of studying bacterially derived molecules by considering different approaches (focusing on common molecules or novel molecules)."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think that's an excellent question because I think there might be molecules that we don't know yet that influence the nervous system. What do you guys think? ",
        "annotations": {
            "propose new idea": "Rosa introduces the idea that there might be molecules unknown to current knowledge that influence the nervous system.",
            "ask question": "Rosa asks for others' thoughts on the possibility of unknown molecules influencing the nervous system."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And so I will go back to um, I think it was Will's question about production or consumption by specific microbes. There there is evidence on on mice that specific microbes will change the concentrations at least in the in the system in the blood of certain chemicals or neurotransmitters and not not all of them have been recognized as neurotransmitters. Um, so those might be important too. What are your thoughts? ",
        "annotations": {
            "develop idea": "Rosa is expanding on an existing idea by providing more information and insights based on evidence.",
            "offer feedback": "Rosa is providing feedback by sharing relevant evidence and insights.",
            "encourage participation": "Rosa invites others to share their thoughts."
        }
    },
    {
        "utterance": "Tom Mansell: also kind of depends probably where it's produced, right? If it's produced near the small intestine, probably has a better chance of getting in the serum. Whereas, you know, in the in the colon, you know, it's probably not as much mass transfer there. ",
        "annotations": {
            "develop idea": "Tom Mansell is expanding on the idea of how microbial metabolites might influence the host by discussing the impact of the location of production within the gut.",
            "offer feedback": "Tom Mansell is providing specific feedback on the idea by highlighting the importance of the location of metabolite production in the gut for its potential effects on the host."
        }
    },
    {
        "utterance": "Tom Mansell: As the chemical engineer, I have to point that out, I guess. That mass transport is a thing. ",
        "annotations": {
            "signal expertise": "Tom explicitly states his background as a chemical engineer to contextualize his comment about mass transport.",
            "offer feedback": "Tom provides a specific perspective about mass transport being relevant, which could be useful for understanding the system being discussed."
        }
    },
    {
        "utterance": "Tom Mansell: So again, I think people a lot of lots of groups brought up biogeography, but um it's definitely something that we need to keep in mind if we're going to harness these this information in some way is, okay, well, this bacterium produces serotonin, well where and how does it get into the serum if so. ",
        "annotations": {
            "develop idea": "Tom Mansell is expanding on the concept of biogeography and its importance in understanding how bacterial products interact with the host.",
            "ask question": "Tom Mansell is asking for information or clarification on how bacterial products like serotonin get into the serum."
        }
    },
    {
        "utterance": "Tom Mansell: And I don't know, you know, you know, there's direct activation of ENS. This is outside of my purview, right? But how would something get to the the brain by the blood brain barrier, I guess? I have to get in the blood first. Right. ",
        "annotations": {
            "ask question": "Tom is requesting information on how substances produced in the gut could affect the brain through the blood-brain barrier.",
            "identify gap": "Tom explicitly states that the topic of direct activation of ENS is outside of his purview, indicating his recognition of a gap in his knowledge."
        }
    },
    {
        "utterance": "Elizabeth Bess: Yeah, I'm interested in what sort of studies people or techniques people think about for tracking um for tracking that. Uh so there's in the 70s and 80s before we were concerned about C14 carbon. There's some beautiful studies that show like the tracking of you know, like pharmacokinetics of drugs, um which we leverage a lot um uh in our lab like going back to use those. When you think about the molecules that are produced endogenously, it does get really tricky to me to think about well even if it's getting produced, where does it go from there? Is it going between cells? Like is it crosses the epithelium is it going through a cell, which could matter in terms of we think a lot about oxidation state. If it goes through a cell, this could change like oxidation state as opposed to between cell. And uh this is something we've struggled with in the lab like thinking about how do you actually track those specific molecules that are getting produced where it's more obvious if it's an exogenous source that you're providing like a carbon, we can use C13 labels too, but how do you do that in vivo um and follow where it goes? And I don't I I I love if someone can answer that or like ideas for how people think about that. ",
        "annotations": {
            "develop idea": "Elizabeth Bess expands on existing ideas about tracking molecules and the challenges associated with it.",
            "ask question": "She asks for opinions and ideas on how to track endogenously produced molecules.",
            "identify gap": "The utterance highlights a gap in knowledge on how to track molecules in vivo.",
            "encourage participation": "Elizabeth Bess invites others to share their thoughts and ideas."
        }
    },
    {
        "utterance": "Linnea Freeman: Um, I just wanted to go, sorry, I don't want to interrupt like I can't uh respond to your question, but I was also thinking about what Tom was saying. I think it connects with what you're just saying too and this is so outside of my area, something I want to listen and get information because I have a lot to learn here, but um in terms of crossing the blood brain barrier, that might not be a major like it's certainly a question, but we don't know if there's um small molecules that are traveling that need to get past the blood brain barrier or if for example, we're talking about serotonin activation that's happening in the gut that could then um stimulate the vagus nerve and that would then send a signal to the brain and then, you know, we might not have to get past the blood brain barrier based on who knows if it's a neurotransmitter like dopamine or serotonin produced in the gut. ",
        "annotations": {
            "develop idea": "Linnea Freeman expands on existing ideas by suggesting an alternative mechanism for how microbial products could influence the brain, involving the stimulation of the vagus nerve.",
            "ask question": "Linnea Freeman poses a question-like structure as part of her contribution, seeking clarification or discussion on the necessity of crossing the blood-brain barrier for microbial products to affect the brain."
        }
    },
    {
        "utterance": "Linnea Freeman: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, yeah, one of the techniques that uh or that I I know Michael Fishbach has done a lot of it, but is this idea of using for the defined microbial communities and then doing genetics within the microbes there. So at least there you can envision that if you know microbe A is responsible for the production of this molecule and you can tune that production in a germ free model and then down the line look at that phenotype, you you might depending on whether or not it's also made by the host, you could conceivably track like, okay, the bugs in the gut, it's making this molecule, it's, you know, it's in the serum, it's in the lamina appropriate. Oh, it doesn't make it into the blood brain, so it's not directly acting in those sort of contexts. ",
        "annotations": {
            "develop idea": "Mark Mimee is expanding on the idea of using defined microbial communities to understand how specific microbes produce certain molecules and how these might affect the host.",
            "offer feedback": "Mark Mimee provides specific suggestions for studying the effects of microbial metabolites on the host, including using defined microbial communities and genetic manipulation."
        }
    },
    {
        "utterance": "Mark Mimee: And I think those models are are pretty powerful um although, you know, scaling it to hundreds of molecules and you know, hundreds of different permutations of uh microbial communities makes that a little bit challenging. ",
        "annotations": {
            "critical response": "Mark Mimee is pointing out a challenge or limitation of the models being discussed, specifically the difficulty in scaling up to hundreds of molecules and permutations of microbial communities."
        }
    },
    {
        "utterance": "Tom Mansell: Our lab's really interested in the idea of privilege substrates, right? So prebiotics are things that not everybody can eat, right? And ideally there you'd have one that nobody can eat, but your proprietary organism, right? Um, and so uh I really I love the idea of a radio labeled prebiotic such that if you have privilege substrate, it's not going to get converted into dopamine or whatever uh unless that bug uh eats it. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea about using radio-labeled prebiotics to track microbial activity.",
            "develop idea": "The speaker elaborates on the concepts of privilege substrates and prebiotics, explaining their potential use."
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, so you'd have to have a sufficiently privileged um substrate to do that. And of course you'd have to make it with C13. ",
        "annotations": {
            "Develop idea": "Tom is building upon previous discussions about substrates, prebiotics, and experimental design, specifically offering thoughts on how to implement a strategy.",
            "Offer feedback": "Tom is providing specific suggestions for how to proceed with experimental design, particularly regarding the use of privileged substrates and C13 labeling.",
            "Signal expertise": "Tom is showing his expertise in areas related to biochemical engineering and experimental design, particularly in the context of microbiome studies."
        }
    },
    {
        "utterance": "Emily Balskus: You would need to also know about the actual metabolic pathways in order to to design Right. a substrate, yeah. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by highlighting the necessity of understanding metabolic pathways to design a substrate, which is a consideration for experimental design in the context of microbiome research."
        }
    },
    {
        "utterance": "Tom Mansell: You need to know which bug makes it, right? ",
        "annotations": {
            "Develop idea": "The speaker is elaborating on the importance of knowing which microbe produces a specific metabolite.",
            "Offer feedback": "The speaker is providing feedback on the necessity of identifying the microbe responsible for producing a metabolite."
        }
    },
    {
        "utterance": "Tom Mansell: And engineer that bug to eat the substrate. Yeah, so that could be the kind of that could be the kind of uh high risk, high reward uh thing we're looking for. ",
        "annotations": {
            "propose new idea": "The speaker introduces the idea of engineering a bug to eat a substrate as a potential approach.",
            "develop idea": "The speaker elaborates on the idea by discussing its potential benefits and risks."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, there is a um heavy labeled muffin actually that can be used for clinical trials, but it's a substrate that many microbes will eat. And I I just know this because at some point I was also thinking about like, can we label the microbes, not just the substrate, but the microbes because it goes in their DNA. Um but but that's I'm muffin. I know this because when I started working on the microbiome, I asked John Debase who was um who is my collaborator at the Mayo clinic and uh he said, yeah, there's an isotopic muffin, but the problem is that this is not too specific. So it won't give you that specific prebiotic stimulation that you're looking for. ",
        "annotations": {
            "express humor": "The speaker makes a joke ('I'm muffin') while discussing research methods."
        }
    },
    {
        "utterance": "Tom Mansell: Right. Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think there's also been some studies that have ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Elizabeth Bess: um leverage the chemical environment as you're traveling through the GI tract to kind of release things at different pH or in different chemical environments, which doesn't have a lot of that is I mean, the precision is not maybe fabulous there, but um could be a way maybe to get some of these small like a C13 labeled molecule to that location because I think that's a big challenge in studying metabolites that if you are like orally dosing some of the metabolites we study, if we orally dose them, they will be immediately absorbed into systemic circulation, but in real life, um that doesn't happen because they're actually um sort of like what Tom's mentioning like part of something that's more complex that doesn't fully get um like perhaps uh hydrolysis of the glucuronide or something. It doesn't happen until you're in the colon and then it releases in the right spot. Um I don't know. So I I don't want to interrupt the conversation, but I've seen that Sarah is very quiet and um we didn't give her a chance to introduce herself because she had to step out. So Sarah, did you want to do a quick introduction and maybe we can hear from you? ",
        "annotations": {
            "develop idea": "The speaker is expanding on an idea about leveraging the chemical environment of the GI tract to release labeled molecules at different pH or chemical environments.",
            "encourage participation": "The speaker invites Sarah to introduce herself and contribute to the conversation."
        }
    },
    {
        "utterance": "Sarah MacEachern: Yeah, sorry. I apologize. I've had to do two days, you know what it's like, you know, patients come first every day. Um Um yeah, I'm I'm a developmental fellow um who's just offered an assistant professor position at the University of Calgary. So I'm sort of like in the very, very early stages. Um my plan is to use precision medicine approaches to approach neurodevelopmental conditions to try to understand them better, but my PhD work was in the neuroscience of the gut, which has sort of brought me back around to this question of um, you know, sort of microbiome and neurodevelopmental conditions. I have to be honest with you for most other sessions I've felt I've been able to follow and it's probably because I came a little late, but um sort of the level of the scientific discussion has been a bit above me, which is in part why I haven't jumped in yet. So it's been part of what I've really enjoyed about the is that I truly have learned so much and like my day-to-day I think looks very different from a lot of you. So um I don't have anything to add quite yet other than to say like you guys are so smart. ",
        "annotations": {
            "signal expertise": "Sarah explicitly states her background, position, and research interests, signaling her expertise in the field.",
            "identify gap": "Sarah mentions that the level of scientific discussion has been a bit above her, indicating a gap in her current knowledge or understanding.",
            "acknowledge contribution": "Sarah acknowledges the intelligence and presumably the contributions of the other participants by saying 'you guys are so smart'."
        }
    },
    {
        "utterance": "Jae Sung: You're so smart. Okay. ",
        "annotations": {
            "Supportive Response": "Jae Sung is expressing agreement and validation for Sarah's contribution to the discussion."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So I I I just want to make sure you you had an opportunity. So let us know raise your hand. ",
        "annotations": {
            "encourage participation": "The speaker explicitly invites others to contribute to the discussion by saying 'So let us know raise your hand,' which encourages participation."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Maybe maybe maybe you can think about how do we measure these in for ",
        "annotations": {
            "encourage participation": "The speaker invites others to think about how to measure certain aspects, encouraging participation in the discussion.",
            "ask question": "The utterance can be seen as asking how to measure certain things, albeit in a suggestive rather than direct form."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: precision medicine actually in humans. So that's one I'm interested in. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Sarah MacEachern: I know that's something I've been wondering about for a while, totally. And worst case I'll just be your guys's hype girl, be like, you know, what's up? ",
        "annotations": {
            "express humor": "The utterance includes humor with the term 'hype girl' and the casual 'what's up?'",
            "encourage participation": "By offering to be their 'hype girl,' Sarah is encouraging participation and showing her support for the group"
        }
    },
    {
        "utterance": "Emily Balakus:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: I think, you know, just to kind of steer the conversation in your direction that, uh, if you, uh, you know, we talk about precision medicine and we thought, okay, well, let's sequence everybody's microbiome and we'll we'll administer a drug based on your microbiome, but, um, what about, you know, the same, not that anybody would have exactly the same microbial composition, right? That would be, uh, very unusual. But like, you know, the same a similar composition might give you totally different phenotypes in a in two hosts, right? And so like maybe there are metabolomic ways of, uh, of doing precision medicine that that where key metabolites are measured and you can say, okay, well, you know, if this person has a lot of build up of X, you know, it means that means something about metabolism of whatever drug of the of the line. Is is that a thing? Um, or are people really focusing on genetics and micro, you know, ",
        "annotations": {
            "propose new idea": "Tom suggests considering metabolomic ways of doing precision medicine, introducing a new approach.",
            "develop idea": "He elaborates on this idea by discussing the potential of measuring key metabolites for understanding drug metabolism.",
            "ask question": "Tom asks if focusing on metabolomics (rather than genetics and microbiome composition) is a thing people are working on, seeking information."
        }
    },
    {
        "utterance": "Jae Sung:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: the first and second genome, let's say as the, um, as the the focus for precision medicine. ",
        "annotations": {
            "clarify goal": "The speaker is discussing the focus of precision medicine, specifically mentioning 'the first and second genome' as potential focuses."
        }
    },
    {
        "utterance": "Mark Mimee: I mean, I think more and more people are looking at the metabolome as as an output for a variety of diseases, either in a targeted way, looking at, you know, other amino acids or short chain fatty acids or bile acids, or there's some efforts to do untargeted metabolomics, but obviously that's really difficult and at least in clinical trials that are starting to get more and more integrated because there's been this appreciation that yeah, knowing the catalog of the bugs that's there is maybe a little bit predictive of what's going on, but it definitely doesn't, uh, show the full picture. So looking at the transcriptional profile or the metabolomic profile, that might be a little bit more informative for, uh, for what's occurring. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of using metabolomic profiles to understand disease, building upon existing knowledge.",
            "identify gap": "The speaker mentions that knowing the microbial catalog 'definitely doesn't show the full picture,' indicating a gap in current understanding.",
            "offer feedback": "The speaker suggests that looking at the transcriptional profile or the metabolomic profile might be more informative for understanding what's occurring."
        }
    },
    {
        "utterance": "Tom Mansell: How do we determine what what are the ones we need to look at? ",
        "annotations": {
            "ask question": "The utterance is a clear request for information on how to determine relevant metabolites or microbial products to study."
        }
    },
    {
        "utterance": "Mark Mimee: Is it metabol, right? Yeah. ",
        "annotations": {
            "ask question": "Mark Mimee is seeking confirmation or clarification on something related to 'metabol.'"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, just like Emily said, we need to know what you're looking for, right? You need to know the pathways. ",
        "annotations": {
            "develop idea": "The speaker is building upon a previous idea about the necessity of understanding or identifying specific elements in their research.",
            "ask question": "The speaker's statement implies a query about the approach or requirements for their research, seeking agreement or clarification."
        }
    },
    {
        "utterance": "Emily Balakus: Yeah, and just to because I think there's kind of two themes in the prompts of kind of discovery and then there's a a mention of the specific kind of neuroendocrine signals like uh neurotransmitters. And so there's kind of we're at different levels of our understanding I think when we sort of consider those two, you know, prompts. ",
        "annotations": {
            "Supportive response": "Emily is acknowledging the complexity and different levels of understanding regarding the themes discussed, showing a positive and supportive attitude towards the conversation.",
            "Summarize conversation": "Emily is trying to summarize or bring together different themes in the conversation.",
            "Clarify goal": "Emily is attempting to clarify the goals or directions of the discussion by highlighting two themes."
        }
    },
    {
        "utterance": "Jae Sung: Tom, did we answer your question about pharmaceutical drugs? You mentioned something about pharmaceutical drugs, right? ",
        "annotations": {
            "ask question": "Jae Sung is requesting information or clarification on whether Tom's question about pharmaceutical drugs was answered."
        }
    },
    {
        "utterance": "Tom Mansell: Oh, well, I just thinking of precision medicine in terms of, uh, you know, dosing or administering particular drugs to a patient. ",
        "annotations": {
            "clarify goal": "Tom is discussing how precision medicine could be applied in terms of drug administration, which relates to defining objectives and outcomes for treatment."
        }
    },
    {
        "utterance": "Tom Mansell: Um, can you use the gut metabolome or the serum metabolome to, uh, make decisions about that, about, you know, uh, liver activity or, uh, you know, uh, those kinds of things. But, you know, in in microbial context, I'm not sure that okay, we used your microbiome and we determined that we should give you this drug. I don't think that that's just using the microbiome is a good probably going to be a good predictor. ",
        "annotations": {
            "ask question": "Tom is requesting information on the use of the gut or serum metabolome for decision-making regarding liver activity or drug administration.",
            "critical response": "Tom is expressing skepticism about the effectiveness of using microbiome data to predict drug responses."
        }
    },
    {
        "utterance": "Will Ludington: Another question, um, kind of I think related to all of this is, um, if there's some signal that's being transmitted from the gut to the brain, like how close is it to saturation? So like if could we do an experiment where we added more of the, you know, the ligand and then we see would it go would whatever we're measuring would it go up or are we basically like a normal person is always saturated and it's only these cases where we get some kind of depletion, something's wrong where where we see an effect. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on a prior statement or idea proposed by another group member, specifically about the saturation level of a signal transmitted from the gut to the brain and potential experiments to test it."
        }
    },
    {
        "utterance": "Elizabeth Bess:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Will Ludington: In which case, you know, there's certain kind of studies that that we're limited to, you know, what we can do. So if and we'd have to do deletion experiments and then the deletion experiments seem like they're really hard. Mark was talking about like using fage, um, but then again that's like you have to design a fage for each species. Um, is it like could we, you know, do like kind of combinatorial like chemical libraries, uh, like just go straight to the metabolites or is there like I think Jay talked about like is there a list, a prioritized list of metabolites, um, that we could kind of come up with, um, that we could kind of add in more and see, you know, give each one to see if it changes our output or is it like or is there a way chemically to deplete certain things like you design an enzyme to break, um, whatever metabolite you're looking for, I don't know. ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the feasibility of certain experimental approaches, specifically regarding deletion experiments and the use of combinatorial chemical libraries or prioritized lists of metabolites."
        }
    },
    {
        "utterance": "Tom Mansell: pharmacodynamics basically versus, you know, most people talk about pharmacokinetics, right? But pharmacodynamics is just important. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Yeah, I think I think that that's a this looks like a job for live, uh, you know, live bacteria in there that would be secreting enzymes that I mean, yeah, you can probably deliver enzymes with certain, uh, uh, world delivery mechanisms, but, you know, supplying different levels of, for example, serotonin or whatever, uh, you can just that this sounds well to me, every, you know, I have a hammer, right? Uh, and this looks like something I can hit with it, uh, you know, in terms of synthetic biology, you can design different promoters that would make different amounts of serotonin and then I I I really like that. ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous discussions about using live bacteria to secrete enzymes and control the production of chemicals like serotonin.",
            "offer feedback": "The speaker suggests using synthetic biology, specifically designing different promoters to control the amount of serotonin produced, as a method to achieve their goals.",
            "supportive response": "The tone of the utterance is positive and supportive towards the idea of applying synthetic biology to produce serotonin."
        }
    },
    {
        "utterance": "Tom Mansell: Uh, that that point of view though in terms of saturation because yeah, you can make all the serotonin you want, but if it's already saturated, who cares, right? ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of serotonin saturation in the context of microbial production.",
            "offer feedback": "The speaker is providing feedback on the practicality of producing serotonin if the system is already saturated.",
            "critical response": "The speaker is critiquing the approach of producing serotonin without considering saturation levels."
        }
    },
    {
        "utterance": "Tom Mansell: Um, yeah, I really like that, uh, um, approach. ",
        "annotations": {
            "Supportive Response": "The speaker is expressing agreement with a previous statement, showing a positive evaluation without adding new content."
        }
    },
    {
        "utterance": "Tom Mansell: But yeah, that's that's certainly something that I can look into it. And and you know, there there are, um, very bugs out there that are engineered, for example, to screen enzymes to get rid of build up of phenyline, um, and uh, oxalic acid and hyper ammonia, right? ",
        "annotations": {
            "Develop idea": "The speaker is expanding on previous ideas by providing specific examples of engineered bugs.",
            "Signal expertise": "The speaker demonstrates expertise by mentioning specific knowledge about engineered bugs and their applications.",
            "Supportive response": "The utterance is supportive as it contributes to the discussion with additional information."
        }
    },
    {
        "utterance": "Tom Mansell: Uh in the gut, um, those are in clinical trials right now. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: Um, not mine, but uh. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Will Ludington:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Pamela Changi: Another crude way to get back on into the linear range is to treat with antibiotics. And then if you can eliminate, if you know which bacteria are making the metabolites of interest, you can then knock down the level and then and then rescue. Um, and then and then you wouldn't be saturated anymore. But it's quite possible a lot of the metabolites are saturating at the steady state. ",
        "annotations": {
            "develop idea": "The speaker is discussing a method to experimentally determine the saturation of metabolites.",
            "offer feedback": "Pamela provides a suggestion for an experimental approach to understand metabolite production and saturation.",
            "None": "No"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So I I want to steer the pot a little bit and say that, um, I've heard great comments about, um, neurotransmitters, metabolites and I can say maybe small molecules, but no one had said anything about metal ions. And I see that that is a title in our topic. So anyone has something you would like to share about metal ions? ",
        "annotations": {
            "ask question": "The speaker is requesting information or insights on metal ions.",
            "encourage participation": "The speaker invites others to contribute their thoughts on metal ions.",
            "process management": "The speaker is managing the conversation flow by steering it towards discussing metal ions."
        }
    },
    {
        "utterance": "Elizabeth Bess: I love metal ions. So, um, I I'm excited to see that in the last couple of years that there's been um an increasing appreciation in the literature for the importance of measuring redox potential of the microbiome. ",
        "annotations": {
            "develop idea": "Elizabeth Bess is expanding on the idea that there's an increasing appreciation for measuring redox potential of the microbiome, indicating her engagement with existing research.",
            "acknowledge contribution": "By mentioning 'there's been um an increasing appreciation in the literature', Elizabeth Bess is verbally recognizing the input of other researchers in the field."
        }
    },
    {
        "utterance": "Elizabeth Bess: and also the difficulty of measuring this. Um, that is, uh, when, um, there have been studies about redox potential in microbial communities for decades, but there's also a huge body of literature that talks about how hard it is to have reproducibility across experiments. So like if you have a redox potential measured in one study, it's probably reasonable to be consistent within a study, but across studies, the numbers that they change by like or like orders of magnitude of 10 or 100, um, that are, um, that are dramatic. And one of the things that, um, I'm interested in if anyone has comments on this is, um, how can we measure metal ions better in the gut and in real time? And this has been a huge challenge in the chemical biology field. ",
        "annotations": {
            "identify gap": "The speaker identifies a gap in the ability to measure metal ions better in the gut and in real time.",
            "ask question": "The speaker asks for comments on how to measure metal ions better.",
            "signal expertise": "The speaker references existing literature on redox potential and measurement challenges, indicating expertise."
        }
    },
    {
        "utterance": "Elizabeth Bess: Um, this is really hard with iron, um, in in the like in a complex system, um, where we are is like synchotron is the only way you can actually measure, um, iron speciation as far as I know right now, um, in, um, biological systems. ",
        "annotations": {
            "identify gap": "Elizabeth Bess is identifying a gap in methodology for measuring iron speciation in biological systems.",
            "signal expertise": "Elizabeth Bess is signaling her expertise by discussing specific measurement techniques and their limitations."
        }
    },
    {
        "utterance": "Elizabeth Bess: So it's like doable, but it's not does anybody know how to use one? I don't. I know you can like get time on these, but um it's really complicated. ",
        "annotations": {
            "identify gap": "The speaker is expressing difficulty and uncertainty about using a specific tool or method, which implies a recognition of a gap in her current capabilities or knowledge."
        }
    },
    {
        "utterance": "Elizabeth Bess: And so it would be um interesting to think about ways to be able to better measure speciation in vivo. You can do this in some ways with like sealgans, there are probes that work to measure iron three specifically in sealgans in a live context. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of measuring speciation in vivo by mentioning specific techniques.",
            "identify gap": "The speaker identifies a gap in the current ability to measure metal ions in vivo.",
            "offer feedback": "The speaker provides specific suggestions for addressing the challenge of measuring speciation."
        }
    },
    {
        "utterance": "Elizabeth Bess:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jae Sung: Elizabeth, um, ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jae Sung: do you do you know if um micro microbes uh they secrete like siderophores? ",
        "annotations": {
            "ask question": "The speaker is requesting information about microbial secretion of siderophores, making this an explicit question."
        }
    },
    {
        "utterance": "Jae-Sung Moon: in the in the gut in in the gut environment. I know it happens in soil, but like is there a lot of insoluble iron in the gut that microbes can kind of sense and be like, hey, I'm going to send out these siderophores to mine for us. Does that happen? ",
        "annotations": {
            "ask question": "The speaker is asking for information about whether microbes can sense insoluble iron in the gut and produce siderophores in response, indicating a request for clarification or expertise."
        }
    },
    {
        "utterance": "Elizabeth Bess: Yeah, yes. So what the the thought is is we make an assumption in the field that iron is mostly in the reduced state in the gut because the gut is a reducing environment, but um, but there are times when there is more iron three oxidized form, which can happen through inflammation, um, through you know, production of Ross or nitric oxide species. Um, but yeah, bacteria do secrete siderophores in uh the the microbiome. The human also secretes enzymes to capture uh iron three, reduce it to iron two so that it can be brought inside of cells. But I think we have a poor understanding of the dynamics of that. Um, how much of the iron is three versus two. I also fascinated that we have that the body it's the iron is so valuable as you know, as we know, for so many processes that there's no way for the body to um, the body doesn't regulate iron levels except for excretion through stool. That's its only way to get like rid of it. Um, and it's um, but we don't understand really the dynamics of what's happening there and um what the the yeah, oxidation states are and how this changes with dysbiosis of a microbiome. Um, what does this mean at like an uh metal a metal level specifically iron is what what I'm you know wonder about. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas about iron dynamics in the gut microbiome, discussing its reduced and oxidized states, and biological responses to it.",
            "identify gap": "The speaker highlights the current lack of understanding regarding the dynamics of iron in the gut, particularly concerning its oxidation states and changes with microbiome dysbiosis.",
            "ask question": "The speaker is implicitly seeking more information or perspectives on the dynamics and implications of different iron states in the microbiome."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And what does it mean for gut brain communication too, right. ",
        "annotations": {
            "ask question": "The utterance is a clear question seeking information or clarification on the implications of something for gut-brain communication."
        }
    },
    {
        "utterance": "Elizabeth Bess: Right. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a previous statement or contribution from another participant."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Any other thoughts? That was amazing. Thank you, Elizabeth. That was fascinating. ",
        "annotations": {
            "encourage participation": "The speaker invites others to contribute their thoughts.",
            "supportive response": "The speaker expresses agreement and positive evaluation for Elizabeth's contribution."
        }
    },
    {
        "utterance": "Emily Baleikus: Maybe to give people just a little bit of a time uh update. I think we have about 20 minutes left. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by providing an update on the time remaining."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So I think in five minutes we should start summarizing. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by suggesting when to start summarizing."
        }
    },
    {
        "utterance": "Tom Mansell: Just on the topic of metal ions here. Um, I uh one thing I wrote down was and this is probably pretty wacky. Um, but uh can you spoof like so some so I'm thinking of of PCR, right? When you do PCR, most of us probably at least have done PCR at least I think. Uh, you use magnesium, but if you spoof in manganese, you screw up the polymerase and it gets error prone, right? Can if you substitute or or or put in like some cobalt or something, uh, you know, in the in the microbiome, I wonder how that would change I'm not saying we don't those people with heavy metals, right? But like uh, you know, something a related uh cat ion, right? It's not like iron probably doesn't have a good um ",
        "annotations": {
            "ask question": "The speaker is asking for thoughts on how substituting or adding certain cations might affect the microbiome.",
            "develop idea": "The speaker is expanding on a known concept (PCR) to explore its implications in the microbiome context."
        }
    },
    {
        "utterance": "Elizabeth Bess: Gallium. Gallium. Okay, yeah. I don't know about that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: That sounds interesting. ",
        "annotations": {
            "supportive response": "The speaker expresses interest and validation for the previous comment about gallium, without adding new content."
        }
    },
    {
        "utterance": "Elizabeth Bess: There's actually a drug. The um there's a drug that's called Gamite, I think. It's gallium nitrate um that is used it um uh is a really good mimic like um chemically for iron. It doesn't have the same redox properties, but it kind of um it binds to enzymes in a similar way that iron does. ",
        "annotations": {
            "develop idea": "The speaker provides an example of a drug (Gamite) that chemically mimics iron, expanding on the discussion about metal ions and their biological effects."
        }
    },
    {
        "utterance": "Tom Mansell: Like just what what would be the if you replaced an animal's iron intake with a little bit of gallium, what would that effect be on the microbiome? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification on the hypothetical scenario of replacing an animal's iron intake with gallium and its effect on the microbiome."
        }
    },
    {
        "utterance": "Emily Baleikus: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: I mean that would probably huge, right? I mean one of the things we work with is E coli Nissle and E coli Nissle is a form of E coli that is probiotic. ",
        "annotations": {
            "develop idea": "Tom Mansell is expanding on the discussion by providing a specific example from his research, mentioning E. coli Nissle, a probiotic form of E. coli, that his lab works with."
        }
    },
    {
        "utterance": "Tom Mansell: You know, just like anything you would go to the store and buy as probiotic. So probably not super good for you, but you can still tolerate it. Uh, but anyway, it's E coli and it it it makes a lot of one of its differences between that and like lab E coli or pathogenic E coli is iron transport. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on the characteristics of E coli Nissle, specifically its differences in iron transport compared to lab or pathogenic E coli, which develops the idea of microbial characteristics and their implications."
        }
    },
    {
        "utterance": "Tom Mansell: Uh and siderophore production. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Tom Mansell: So like it transports iron like crazy and in doing so takes over the E coli and Shigella on Shiga toxin producing E coli niche. So, um like that that to me seems like a great like interface, right? ",
        "annotations": {
            "Develop idea": "The speaker is expanding on how E. coli Nissle works and its implications.",
            "Signal expertise": "Tom Mansell is explicitly stating his understanding and knowledge of E. coli Nissle's behavior."
        }
    },
    {
        "utterance": "Emily Baleikus: And so cool. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Emily Baleikus: One other quick metal fact that I found really interesting is that if you like look into the defects that germ free mice have, um, impaired metal homeostasis is actually a really big thing. ",
        "annotations": {
            "code name": "None",
            "explanation": "The utterance shares an interesting fact but does not directly fit into the provided codes in a clearly applicable way."
        }
    },
    {
        "utterance": "Emily Baleikus: Like they have problems with metal uptake. Uh, and I'm not really sure that we understand why. So I think there's a lot of a lot of interesting metal chemistry potentially going on in the microbiome that we just we don't understand. ",
        "annotations": {
            "identify gap": "The speaker expresses uncertainty about why germ-free mice have problems with metal uptake.",
            "propose new idea": "The speaker suggests there's a lot of interesting metal chemistry potentially going on in the microbiome that is not yet understood."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think I would summarize the the the the metal scenario as uh what Elizabeth mentioned for um redox uh conditions or electron acceptors. I think that's um a way to think about it and as um uh enzyme cofactors. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing the conversation about metal ions, specifically referencing aspects mentioned by another participant."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: So there's two different categories that these metals are really needed for those two things. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the discussion about metal ions by categorizing their needed roles."
        }
    },
    {
        "utterance": "Tom Mansell: So what's needed according to Elizabeth, I guess in this field or this sub sub sub area is um uh really good sensors or or for in vivo metal content, not only by element or ion type, but by species of that element, right? So Elizabeth if you had an iron three versus iron two sensor that would would give you a read out in vivo in in feces that would be pretty cool. ",
        "annotations": {
            "identify gap": "The speaker identifies a gap in current technology regarding measuring metal ions.",
            "develop idea": "The speaker is expanding on Elizabeth's idea about the importance of understanding metal ions in the microbiome.",
            "ask question": "The utterance contains a question directed at Elizabeth, inquiring about the possibility of having a sensor for iron three versus iron two."
        }
    },
    {
        "utterance": "Elizabeth Bess: I would be so happy. Yes. Yes, that would um yeah, I think that is I think many people would be so happy. But specifically for iron three and not activated by iron two or any other trivalent. ",
        "annotations": {
            "supportive response": "The speaker expresses enthusiasm and agreement with the idea of developing a sensor for iron three.",
            "identify gap": "The speaker highlights the need for a sensor specific to iron three that is not activated by iron two or other trivalent ions."
        }
    },
    {
        "utterance": "Tom Mansell: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lisa Osborne: Sure. Uh I I'm trying to put them onto the sorry, I'm just trying to find the right button here. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lisa Osborne: Just trying to get my notes from here onto um our actual slide here. ",
        "annotations": {
            "process management": "The speaker is trying to organize their materials by transferring notes to a slide, which relates to managing the flow of work or presentation."
        }
    },
    {
        "utterance": "Lisa Osborne: So so far what I've got is I heard a lot about sort of known knowns or known unknowns versus unknown unknowns. Let's get that together. So whether or not um there's benefit to looking at targeted versus untargeted metabolomics and if you do have a candidate that you're interested in like really following the mechanism of how this metabolite is getting across the blood brain barrier acting locally on a Vegas nerve, um what it might be doing to the gut, which cell types might be interacting with or the opposite approach of just like this is everything that exists and they happen to be different. The metabolite black box is different in a disease state versus a healthy state. And so that means that there is something going on and then what are the next steps for characterizing and understanding what those differences mean. ",
        "annotations": {
            "develop idea": "Lisa is expanding on previous discussions by suggesting ways to approach the study of metabolites, such as considering targeted vs. untargeted metabolomics.",
            "ask question": "Lisa is asking questions about the benefits of different approaches to studying metabolites and how to understand their effects.",
            "summarize conversation": "Lisa is summarizing her understanding of the conversation, highlighting key points and areas of discussion."
        }
    },
    {
        "utterance": "Lisa Osborne: getting the rest of this over here. Uh, there was a good conversation about tracking these metabolites and so different approaches to doing that. Um, C13 labeling, like I think it was Elizabeth was saying it's really easy if you know what candidate you're looking at, you can make a C13 label and then you can follow that in the gut, in the tissues all the way up to the brain if that's what you're interested in. But if you don't want to provide an exogenous signal, how do you get how do you have that same tracking capability? And so there was this discussion of genetically tractable microbes, either under or over expressing something or using these privileged substrates and whether or not we can I think the the idea was labeling the substrate and then following that through the bug and then through the host, is that right? ",
        "annotations": {
            "summarize conversation": "The speaker summarizes previous discussions on tracking metabolites, mentioning C13 labeling and genetically tractable microbes.",
            "ask question": "The speaker seeks clarification on how to track metabolites without providing an exogenous signal."
        }
    },
    {
        "utterance": "Elizabeth Bess: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it's a minimal response"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Yeah, I think the idea was following the metabolites produced by the by the either the micro or the host that will be labeled because they come from that substrate. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lisa Osborne: Yes. Okay. Um, and then even targeted ways of getting that substrate to a certain area. So I guess the idea would be like if you know that a microbe lives in the small versus the large intestine, depending on pH or osmolality or some other physical signal, that substrate could be released in an area where the microbe of interest would be able to have access to it. Again, is that an accurate reflection of what was being said? ",
        "annotations": {
            "develop idea": "The speaker is expanding on previous ideas by suggesting targeted ways of releasing substrates.",
            "ask question": "The speaker seeks confirmation or clarification with the question at the end.",
            "offer feedback": "The speaker provides a suggestion for how to target substrates."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: I think so. I think Tom also mentioned that if we could um identify a specific substrate that will stimulate a very specific microbe then, right? Is that what you said, Tom? ",
        "annotations": {
            "Ask question": "Rosa Krajmalnik-Brown is seeking confirmation from Tom about his previous statement.",
            "Acknowledge contribution": "Rosa Krajmalnik-Brown is acknowledging Tom's previous input by referencing it and asking for confirmation.",
            "Summarize conversation": "Rosa Krajmalnik-Brown is summarizing or recalling a point previously made by Tom to ensure understanding."
        }
    },
    {
        "utterance": "Tom Mansell: Right. Um, and it could be that you you may have to artificially create that. But yeah. I'm sure there's you know, certain things that I mean fiber, right? Fiber is good for you, probably leads to other things besides. ",
        "annotations": {
            "develop idea": "Tom is expanding on the idea of creating specific substrates to stimulate certain microbes.",
            "supportive response": "Tom is expressing agreement and a positive view on the idea.",
            "offer feedback": "Tom is providing a suggestion by mentioning the artificial creation of substrates."
        }
    },
    {
        "utterance": "Lisa Osborne: Um, and then this was a really interesting bit, the value of measuring these levels of metabolites. Um, so even if you measure that there's a difference, say between again like a healthy versus a disease state, what is the impact of that? So you know you have a difference, but is the disease state say if it's got a reduced level of short chain fatty acids in the circulation, is that still saturation for that that person? Um, and is there a way that we can overcome that uh or would the way that we deliver said drug, if it's a short chain fatty acid for example, if we just feed that into the diet versus uh changing the microbiota so that we increase short chain fatty acid capability from the from the microbiota itself, does does that have an effect on the pharmacodynamics of the drug's ability or access to a different tissue site. Um, and then finally, this conversation about metal ions, there's a lot that sort of was happening while I was trying to get these notes um together, but it sounded like ultimately really there are indications that the microbiota has something to do with uh heavy metal metabolism. There's a lot that we don't understand and technically we don't we don't understand it because there are so many technical challenges just in terms of measurement, reporting across studies and one thing that could really advance the field here would be sensors for metal content and species uh in vivo in real time and then within that looking for whether or not these heavy metals are acting as electron acceptors or versus enzyme cofactors. How do we feel about this? ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas about measuring metabolite levels and their implications.",
            "ask question": "The utterance contains several questions about the impact of metabolite levels and the role of metal ions.",
            "identify gap": "The speaker highlights gaps in understanding metal ion metabolism and the need for better measurement tools.",
            "offer feedback": "The speaker suggests developing sensors for metal content to advance the field.",
            "summarize conversation": "The utterance summarizes key points from the discussion on metabolites and metal ions.",
            "encourage participation": "The speaker asks for opinions, encouraging group participation."
        }
    },
    {
        "utterance": "Elizabeth Bess: Good. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jae Seungh: Very well uh transcribed. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lisa Osborne: Okay. Um, I am going to stop sharing and mute myself again and just continue adding, but if you guys want to just continue discussing, I'll try and oh sorry, Sarah, I misspelled your name on that. Um, I'll just keep doing this. Uh, any of you guys want to chat, I'll try and add whatever I can as you as you go. ",
        "annotations": {
            "process management": "Lisa is managing the meeting flow by stating she will stop sharing and mute herself.",
            "encourage participation": "Lisa invites others to contribute by asking if any of them want to chat."
        }
    },
    {
        "utterance": "Elizabeth Bess: I can do that if you would like a break. But if you want to do it, go for it. ",
        "annotations": {
            "supportive response": "The utterance expresses support and willingness for either the speaker or another to take over summarizing, showing a positive and cooperative attitude."
        }
    },
    {
        "utterance": "Lisa Osborne: Uh, no, if you want to if you want to do it, absolutely happy. I mean you had a lot to to add to the discussion, so I think you're a good represent representative for us. ",
        "annotations": {
            "acknowledge contribution": "Lisa Osborne acknowledges Elizabeth Bess's contributions to the discussion.",
            "supportive response": "The utterance expresses agreement and positive evaluation for Elizabeth Bess."
        }
    },
    {
        "utterance": "Elizabeth Bess: Happy to do it. Thanks for all the good note taking. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input (note-taking).",
            "supportive response": "The speaker expresses a positive sentiment towards the note-taker's effort."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: That's great. Uh, Lisa, remember we only have one one slide. Yeah. Let's stick to one slide. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by reminding participants about the presentation format, specifically suggesting to stick to one slide."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: And just um highlights salient points. ",
        "annotations": {
            "process management": "Rosa Krajmalnik-Brown is suggesting a way to manage their discussion by highlighting salient points."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, I thought I'd bring up in the last couple minutes. Um, I know there's um uh work that's at least gone on in the sort of synbio microbiome space of using engineered bugs as kind of metabolic sinks within the microbiome. So not necessarily caring about their natural activity whatsoever, uh but the two examples that were in PKU where there's accumulation of phenyllalanine and as well as in hyperammonemia, kind of the idea of engineering bugs to scavenge those since they are circulated through the gut. Um, and it's kind of very indirect. They are um associated with neurological diseases. Um, but they're not necessarily associated with the microbiome, but it's at least another thought of maybe we don't even need to understand really what's going on and really just use the microbiome as an agent through which we could engineer the metabolome of the host provided these molecules are, you know, going through inter circulation and that's something. ",
        "annotations": {
            "propose new idea": "Mark introduces the concept of using engineered bugs as metabolic sinks within the microbiome.",
            "develop idea": "Mark elaborates on this idea by providing specific examples (PKU and hyperammonemia) and explains how it could work.",
            "offer feedback": "Mark suggests using engineered bugs as a potential approach to addressing neurological diseases through microbiome engineering."
        }
    },
    {
        "utterance": "Tom Mansell: Elizabeth, I know you're busy, but is is iron three more of an indicator of disease or is the fact that there is that species around, is that what actually serves as a catalyst for um you know, is it is it causal or correlative that the iron three is around during certain disease states? ",
        "annotations": {
            "ask question": "Tom Mansell is asking Elizabeth a question about the role of iron three in disease states, seeking clarification on whether it is an indicator, catalyst, or merely correlative.",
            "develop idea": "Tom Mansell is building on the previous discussion about metal ions, specifically questioning the role of iron three in disease states."
        }
    },
    {
        "utterance": "Elizabeth Bess: Um, I would say there's an element of both. Uh, I think that we think that there's a increase as a field we think there's, you know, an increase in iron three is a consequence of uh inflammation of Ross, but I think that we're also seeing in a few interesting contexts of um there was a paper in E life 2018 ish. Um, that uh from Warren Stevens group uh where they uh gave mice antibiotics and they see differences in redox potential. Um, and it would be uh interesting to see like how does that actually change ironciation as a consequence of of antibiotics as well and what sort of readouts does this end up um or impacts does this end up having on the the activity of them bacteria just because now as I think you had mentioned or um I mean was Jay like uh umphores, like now maybe that we have iron three bacteria producing morephores. Um, which could also induce I think more pathogenicity as well. Um, when there's more iron three around, which has been seen in other contexts. ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas about the role of iron three in the microbiome and its potential effects on bacterial activity and pathogenicity.",
            "signal expertise": "The speaker references specific research and concepts, demonstrating their expertise in the field of microbiome and metal ion interactions.",
            "identify gap": "The speaker highlights the need for further research into the dynamics of iron speciation in the gut and its impacts on microbial activity."
        }
    },
    {
        "utterance": "Tom Mansell: Some antibiotics arephores. ",
        "annotations": {
            "Critical response": "The speaker makes a statement that could be seen as critiquing or adding a nuance to previous discussions, possibly about the relationship between antibiotics and microbial iron acquisition mechanisms."
        }
    },
    {
        "utterance": "Elizabeth Bess: Yep. ",
        "annotations": {
            "None": "The utterance 'Yep.' is a brief acknowledgment without adding significant content."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Right shuttles. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Right, shuttles. You have shuttles also. You have molecules that are shuttles. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by mentioning 'shuttles' and 'molecules that are shuttles,' likely building on prior discussion.",
            "acknowledge contribution": "The speaker is also implicitly acknowledging and possibly expanding on a previous contribution regarding 'shuttles.'"
        }
    },
    {
        "utterance": "Mark Mimee: the concern there is like it's fine for the person, but after they excrete it then where does it go? And that's where the EPA gets in and that's where the concerns uh really are. And also for the ethical dilemma of like, well, you could spread a microbiome from one person to another if you're in the same household. And even if person A is sick and is perfectly fine with eating an engineered bug, but you know, their brother or sister or spouse or kid is not and it transfers to them, then they've been unknowingly dosed with a drug. So there's definitely some ethical um issue there. But regardless, it seems like, you know, they're trying to grapple with the the ethics both on the environmental and the medical side of that and it's all moving forward uh at least from my opinion. It's not something it's something that should be figured out and not something that should be necessarily a bar to the field in general. ",
        "annotations": {
            "critical response": "The speaker is expressing concerns and questioning the potential consequences of using engineered microbes, highlighting ethical and environmental issues."
        }
    },
    {
        "utterance": "Jae Sung: Thank you. Mark on that line like, I mean, this is this is probably related to your your line of work, but is there uh companies that are engineering, you know, bugs and and actually doing clinical trials like for particular diseases? ",
        "annotations": {
            "ask question": "The speaker is requesting information about companies that are engineering microbes for clinical trials, indicating a need for clarification or knowledge on this topic."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah. Yeah, so the furthest yeah, there's a couple of them. Um so there's definitely folks in the cancer space that have been doing it for a really long time. Uh there's one company that was uh I I mean active biotics. I think it's been acquired by a bunch of different people so I don't even know what it's called anymore. And there's another one based in Boston uh called Synlogic. Um these are all in like phase two trials, all orally dosed. I know some folks that worked at Synlogic and their clinical trial was giving people a half a liter of bacterial culture at a concentration of like 10 to the 11 CFU per mill. And that was approved by the FDA. So it's like really high dosing of bugs going into people um and they've had good phase two results I think or phase 1A phase 1B sorry, phase two results and they're moving forward from there. So ",
        "annotations": {
            "develop idea": "Mark Mimee is expanding on the concept of engineering microbes for therapeutic purposes by providing specific examples of companies and their progress in clinical trials."
        }
    },
    {
        "utterance": "Jae Sung: Got it. It's it's happening is the short answer. Got it. ",
        "annotations": {
            "None": "The utterance primarily serves as a general acknowledgment of information received without specifically fitting into one of the other code categories."
        }
    },
    {
        "utterance": "Jae Sung: What disease though? ",
        "annotations": {
            "ask question": "The speaker is requesting information about a specific disease being targeted in the context of microbiome research and engineering bugs for therapeutic purposes."
        }
    },
    {
        "utterance": "Mark Mimee: Uh so that was the I think that was the PKU example. Um I think they also had a phase one ",
        "annotations": {
            "develop idea": "Mark Mimee is building upon or elaborating on a previous idea or discussion about the PKU example and its phase one study.",
            "summarize conversation": "Mark Mimee is attempting to summarize or recall previous discussions."
        }
    },
    {
        "utterance": "Mark Mimee: uh thing for hyperammonemia that uh wasn't as positive so they're going forward with PKU. And now them as well as almost everyone else is going after cancer immunotherapy as well. trying to use those as to modulate the the the utility of those drugs. So I think those I mean those pertain to this, but you know, a lot of people are thinking about that. ",
        "annotations": {
            "develop idea": "The speaker expands on existing knowledge about medical treatments and research directions.",
            "supportive response": "The speaker positively evaluates efforts in cancer immunotherapy.",
            "clarify goal": "The speaker discusses the goal of using therapies to modulate drug utility."
        }
    },
    {
        "utterance": "Jae Sung: How do you get those bugs out? ",
        "annotations": {
            "ask question": "The speaker is requesting information on how to remove engineered bugs, indicating a need for clarification or expertise from other team members."
        }
    },
    {
        "utterance": "Jae Sung: After after the job's done. ",
        "annotations": {
            "ask question": "The speaker is requesting information on how to handle or remove engineered bugs after they have served their purpose."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, oh so most of them are engineered with auxotrophies so that they're like only uh by the time they're excreted, they're already dead is the way that these things are. So none of these applications are of like trying to colonize a host for months on end and for them to dynamically respond. They're mostly just using the bugs as like bags to carry enzymes or some relatively complex system so that I can carry out an activity and then sort of self-destruct by the time they leave. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on how engineered bugs are designed to work, specifically mentioning auxotrophies and their applications.",
            "signal expertise": "The speaker is showing expertise in the field of engineering microbes for medical applications, explaining design considerations and purposes."
        }
    },
    {
        "utterance": "Jae Sung: I see. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mark Mimee: But they could always evolve uh ways around these kill switches. ",
        "annotations": {
            "identify gap": "The speaker points out a potential gap or problem in using kill switches in engineered bugs.",
            "critical response": "The utterance critically evaluates the effectiveness of kill switches.",
            "offer feedback": "The speaker provides feedback on the potential vulnerability of kill switches."
        }
    },
    {
        "utterance": "Mark Mimee: That's where a good deal of the concern is. ",
        "annotations": {
            "critical response": "The speaker is expressing concern about the potential risks associated with engineered bugs, specifically the possibility that they could evolve in ways that undermine their intended function."
        }
    },
    {
        "utterance": "Will Ludington: Yeah, do people look at the I mean the temperature is a major factor in terms of uh how well something can deal with an auxotrophy. Um so and often times like lower temperature makes things more tolerant. Um is that like in in that field? Is that a uh I mean there I assume they're engineer at 37 degrees but then they get on the environment and they're at, you know, significantly less than 37 degrees. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the consideration of temperature in microbial engineering, specifically concerning auxotrophy.",
            "develop idea": "The speaker is expanding on the concept that temperature affects microbial tolerance, particularly for engineered microbes with auxotrophies."
        }
    },
    {
        "utterance": "Mark Mimee: Yeah, and I know like even um there's like some stuff out of Pen Silver's group which was using that temperature differential as an indicator that a bacteria is escaping the body and therefore should self-destruct. So could kind of detect that it wasn't room temperature, it's ingested, goes up to 37 at that point it turns on its therapeutic capabilities and then when it goes back out the other end and it drops back down to room temperature so that's when it's going to initiate the whole self-destruct mechanism. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on an existing idea by explaining a specific approach to engineering bacteria, including a self-destruct mechanism based on temperature differentials.",
            "signal expertise": "The speaker is demonstrating his knowledge of scientific literature and techniques in the field of synthetic biology and microbiome engineering."
        }
    },
    {
        "utterance": "Mark Mimee: At least some people are thinking about that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Mark Mimee: We don't work on that. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: We have uh about a minute left. Lisa, how are you doing with that? Uh it is messaged Elizabeth. It's uh done and she's taken a look at it now to see make sure she knows what she wants to say, I think. Yes. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by informing about the remaining time and checking on task progress."
        }
    },
    {
        "utterance": "Lisa Osborne: Yeah, Lisa did a really nice job organizing all of those like everyone's thoughts. It looks really nice. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input, specifically Lisa's effort in organizing everyone's thoughts."
        }
    },
    {
        "utterance": "Lisa Osborne: This was a really like I'm sorry that I didn't have much to add uh listening to you guys, but so much fun to think about and this this particular conversation seemed like the one that really uncovered like we don't know what we're doing. Like there is so much. Like it seemed like every other conversation that was in there was like, you know, like everybody's got their own bits of expertise and areas that they're looking at, but this is just black boxish is fun. ",
        "annotations": {
            "express humor": "The speaker makes a humorous comment about the complexity of the conversation topic, referring to it as 'black boxish is fun'.",
            "summarize conversation": "The speaker summarizes her impression of the conversation, noting that it uncovered areas where they lack knowledge and highlighting its complexity."
        }
    },
    {
        "utterance": "Jae Sung: I I really like this type of, you know, conference. It's like everybody just gets together from various domains and just talk and just, you know, a nice theme comes out just organically. You know, rather than the conferences we're used to, we just listen and just listen to talks, you know, talk by talk by talk and hopefully get to ask questions, but this was really fun and very good creative exercise. Um, thanks for all the facilitators, Emily and Rosa for uh, you know, helping us with organize everything. ",
        "annotations": {
            "supportive response": "Jae Sung is expressing a positive evaluation of the conference format and thanking the facilitators, which is a supportive and encouraging response."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Uh we're going to close in 30 seconds. I don't see the update yet on the slides. Um so I don't know if Lisa or Elizabeth is going to put it up. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow and time, indicating the meeting is about to close and checking for final updates on the slides."
        }
    },
    {
        "utterance": "Elizabeth Bess: Um I think I see it. Uh maybe I'm looking at the wrong spot though. I see 3.1 key points. Is that the right spot? ",
        "annotations": {
            "ask question": "The speaker is requesting confirmation or clarification on what she is seeing."
        }
    },
    {
        "utterance": "Lisa Osborne: I hope so. That's where I put it. ",
        "annotations": {
            "supportive response": "Lisa Osborne is expressing agreement or confirmation."
        }
    },
    {
        "utterance": "Elizabeth Bess: Okay, I see it. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Elizabeth Bess: I see it too. ",
        "annotations": {
            "supportive response": "The utterance expresses agreement and validation of the previous speaker's statement."
        }
    },
    {
        "utterance": "Rosa Krajmalnik-Brown: Okay. Thanks everyone. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Elizabeth Bess: Thanks. ",
        "annotations": {
            "acknowledge contribution": "The speaker is verbally recognizing another group member's input."
        }
    }
]